ACC Board Approves Unaudited Financial Results, Senior Management Changes

ACC’s Board of Directors has approved the unaudited financial results for Q3 2026 and the nine months ended December 31, 2025. The results, reviewed by the Audit Committee, showcase the company’s performance. Furthermore, there have been key changes in senior management personnel, including the appointment of Mr. Sanjay Kumar Behl as Head – Sales, Marketing and Logistics, and Col. Ravinder Rajput as Head – Security, effective February 1, 2026.

Financial Results Approved

The Board of Directors has officially approved the unaudited financial results (standalone and consolidated) for Q3 2026 and the nine months ending December 31, 2025. These results have undergone a thorough review by the Audit Committee, ensuring compliance and accuracy.

Senior Management Changes

There have been key changes in the company’s Senior Management Personnel (SMP), demonstrating a strategic realignment. The changes are:

  • Appointment of Mr. Sanjay Kumar Behl as Head – Sales, Marketing and Logistics, effective February 1, 2026. He brings experience from FMCG, telecom, lifestyle, and mobility sectors.
  • Appointment of Col. Ravinder Rajput as Head – Security, effective February 1, 2026. He is replacing Col. Bhawar Singh, who will cease to be SMP with effect from the close of business hours on January 31, 2026, and will assume a new role at Adani group level.

Key Financial Highlights

Key financial figures from the standalone unaudited results:

  • Revenue from Operations: ₹6,366.82 Crore for Q3 2026.
  • Total Income: ₹6,516.77 Crore for Q3 2026.
  • Profit Before Tax: ₹595.50 Crore for Q3 2026.
  • Profit After Tax: ₹541.40 Crore for Q3 2026.

The Board remains focused on growth and operational efficiency, adapting to evolving market dynamics and solidifying the company’s position in the cement industry.

Source: BSE

Previous Article

ACC Robust Q3 FY26 Performance Driven by Volume Growth

Next Article

Shilpa Medicare Orphan Drug Designation Granted for Rare Blood Cancer Treatment